Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done

Vera Therapeutics, Inc.

2024-Q3 EPS reported -$2.03

Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
Completed $345M public equity offering to fund atacicept launch and regulatory submission.
Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.
Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.
Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.